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A B S T R A C T
Tay-Sachs disease is a severe lysosomal storage disorder caused by mutations in Hexa, the gene that encodes for
the α subunit of lysosomal β-hexosaminidase A (HEXA), which converts GM2 to GM3 ganglioside. Unexpectedly,
Hexa−/− mice have a normal lifespan and show no obvious neurological impairment until at least one year of
age. These mice catabolize stored GM2 ganglioside using sialidase(s) to remove sialic acid and form the gly-
colipid GA2, which is further processed by β-hexosaminidase B. Therefore, the presence of the sialidase (s)
allows the consequences of the Hexa defect to be bypassed. To determine if the sialidase NEU3 contributes to
GM2 ganglioside degradation, we generated a mouse model with combined deficiencies of HEXA and NEU3. The
Hexa−/−Neu3−/− mice were healthy at birth, but died at 1.5 to 4.5 months of age. Thin-layer chromatography
and mass spectrometric analysis of the brains of Hexa−/−Neu3−/− mice revealed the abnormal accumulation of
GM2 ganglioside. Histological and immunohistochemical analysis demonstrated cytoplasmic vacuolation in the
neurons. Electron microscopic examination of the brain, kidneys and testes revealed pleomorphic inclusions of
many small vesicles and complex lamellar structures. The Hexa−/−Neu3−/− mice exhibited progressive neu-
rodegeneration with neuronal loss, Purkinje cell depletion, and astrogliosis. Slow movement, ataxia, and tremors
were the prominent neurological abnormalities observed in these mice. Furthermore, radiographs revealed
abnormalities in the skeletal bones of the Hexa−/−Neu3−/− mice. Thus, the Hexa−/−Neu3−/− mice mimic the
neuropathological and clinical abnormalities of the classical early-onset Tay-Sachs patients, and provide a sui-
table model for the future pre-clinical testing of potential treatments for this condition.
1. Introduction
The GM2 gangliosidoses (Tay-Sachs, OMIM 272800; Sandhoff,
OMIM 268800; and GM2AP deficiency, OMIM 272750) are a group of
rare lysosomal storage disorders caused by mutations in three different
genes: Hexa, Hexb, and Gm2ap. The Hexa and Hexb genes encode the α
and β subunits, respectively, of β-N-acetylhexosaminidase, (HEXA, αβ,
EC 3.2.1.52), which form a complex with GM2AP to hydrolyze GM2
ganglioside and remove N-acetylgalactosamine (Gravel et al., 2001).
GM2 ganglioside is a glycosphingolipid that serves as an intermediate
in complex brain ganglioside (mainly GM1a, GD1a, GD1b, and GT1b)
biosynthesis and degradation (Kolter and Sandhoff, 1999). Complex
brain gangliosides are most abundant in the cell membranes of neurons,
where they contribute to axon-myelin interactions, Ca2+ homeostasis,
and the activity of a diverse range of trans-membrane receptor signaling
pathways (Regina and Hakomori, 2008; Schnaar, 2010; Ohmi et al.,
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2012; Nordstrom et al., 2013; Allende and Proia, 2014). Therefore, the
central nervous system is the most impacted organ in patients because
of the high levels of the HEXA substrate, GM2 ganglioside. Tay-Sachs
disease is clinically similar to Sandhoff disease and GM2-activator de-
ficiency (Sandhoff, 2016). The classic infantile acute form begins early
in infancy and leads to death by four years of age. It is also known as
early-onset type I GM2 gangliosidosis (B variant or pseudo-AB variant).
Variable phenotypes with a range of disease severities and ages of onset
result when low levels of residual HEXA activities are present (Sandhoff
and Conzelmann, 1984). Juvenile subacute (the onset can be between
two and ten years of age) and chronic (onset in adult life) forms of the
disorder can occur. Patients with the rapidly progressive and acute form
of this disorder exhibit a total or near-total loss of HEXA activity that is
mostly due to missense or nonsense mutations. Diagnosis can be made
by a number of methods, such as measurement of HEXA enzyme ac-
tivity using synthetic substrates. The clinical symptoms of progressive
neurodegeneration and developmental delay are caused by the accu-
mulation of GM2 ganglioside in lysosomes, which leads to early cell
death in Tay-Sachs patients.
Two independent studies attempting to generate mouse models of
GM2 gangliosidoses by targeting the mouse Hexa and Hexb genes
yielded unexpected results (Phaneuf et al., 1996; Yamanaka et al.,
1994). The disruption of Hexb resulted in a severe neurological phe-
notype similar to Sandhoff disease; however, the disruption of Hexa
resulted in nearly normal mice rather than a severe early-onset neu-
rological phenotype. These findings were explained by the presence of
one or more sialidases in mice that can remove sialic acid from GM2
ganglioside to create GA2 ganglioside, which can then be degraded by
the HEX B (ββ) present in HEXA- deficient Tay-Sachs mice (Fig. 1A)
(Sango et al., 1995; Yuziuk et al., 1998). The generation of a HEXB-
deficient Sandhoff disease model in mice was useful for the initial
evaluation of potential therapies for the GM2 gangliosidoses. However,
Hexa−/− mice have proven to be of little value as a model for Tay-
Sachs disease because they do not exhibit a severe buildup of brain
GM2 or the abnormal behavioral manifestations that are seen in human
Tay-Sachs patients.
Sialidases or neuraminidases (EC 3.2.1.18) are a family of exo-gly-
cosidases that cleave non-reducing sialic acids that are glycosidically
linked to the saccharide chains of glycoproteins, glycolipids or oligo-
saccharides. Sialidases have been implicated in crucial biological pro-
cesses, including regulation of proliferation, control of cell adhesion,
modeling of myelin, and metabolism of glycoconjugates (Monti et al.,
2010). In humans, sialidases are encoded by multiple genes and they
differ in terms of their optimal working pH values, kinetic properties,
substrate specificities, and preference for sialic acid linkage. Based on
their subcellular localization, the sialidases can be categorized as ly-
sosomal (NEU1), cytosolic (NEU2), plasma- membrane-associated
(NEU3), or lysosomal/mitochondrial or intracellular-membrane-asso-
ciated (NEU4) (Miyagi and Yamaguchi, 2012). NEU1, NEU3, and NEU4,
are capable of hydrolyzing sialic acid residues from gangliosides.
However, the lysosomal sialidase NEU1, is part of a multi-enzyme
complex with β-galactosidase and protective protein-cathepsin A
(Pshezhetsky and Ashmarina, 2001) and is inactive outside of the
complex, and it undergoes rapid degradation in cells deficient in ca-
thepsin A in the genetic disease galactosialidosis (Bonten et al., 2009).
NEU1 is the only mammalian sialidase that is clinically relevant with
NEU1 deficiency resulting in the accumulation of sialoglycoconjugates,
and extensive lysosomal vacuolization, causing excessive tissue de-
generation and a pediatric neurosomatic disorder (d'Azzo et al., 1982).
NEU3 is highly active toward gangliosides, and in addition to being
located on the plasma membrane, it can also be found facing inward on
the membranes of endosomes and lysosomes (Miyagi et al., 1999; Monti
et al., 2000; Zanchetti et al., 2007; Albohy et al., 2010). The principal
substrates of NEU3 are GM3 and disialogangliosides such as GD1a
(Papini et al., 2004; Ha et al., 2004) and it exhibits poor activity toward
GM1 or GM2, at least in vitro (Wang et al., 2001). NEU4 is targeted to
Fig. 1. (A) Schematic illustration of part of the degradation pathway of glycosphingolipids. NEU3 is the primary enzyme responsible for the metabolic bypass in the Hexa−/− mouse
model. (B, C) Expression levels of (B) Neu1 and (C) Neu3 were quantified by RT-PCR for RNA isolated from four different regions of Hexa−/− and WT mouse brains and are represented as
the ratio of the gene of interest to the GAPDH gene. Data represent the mean ± SE. Statistical analysis was performed using one-way ANOVA (*p < 0.05, **p < 0.025, and
****p < 0.0001).
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subcellular compartments but is more widely distributed. It has been
reported to be found in the endoplasmic reticulum (ER), mitochondria
(Yamaguchi et al., 2005), and lysosomes (Seyrantepe et al., 2008). In
our previous study, we also reported that NEU4 exhibits activity toward
complex gangliosides and GM2 ganglioside in vitro (Seyrantepe et al.,
2008). In an attempt to elucidate whether the sialidase NEU4 is in-
volved in bypassing the metabolic defects in Hexa−/− mice, we gen-
erated a Hexa−/−Neu4−/− mouse model. The relatively mild pheno-
type in that model underscored the sialidase NEU4 as a modifier gene
rather than a major player, leaving unclear the identity of the
Table 1
UPLC gradient used for the LC-ESI-MM/MS analysis of GSLs.
Time (min) Flow (mL) Solvent A (%) Solvent B (%) Curve
Initial 0.45 100 0 Linear
0.25 0.45 100 0 Linear
1.00 0.45 50 50 Linear
5.50 0.45 0 100 Convex
6.50 0.45 0 100 Linear
7.00 0.45 100 0 Linear
7.50 0.45 100 0 Linear
Fig. 2. (A) Body weights of Hexa−/−Neu3−/− (n= 12), Hexa−/− (n= 17) and Neu3−/− (n= 12) mice over 20 weeks are presented as a proportion of the body weights of the WT
(n= 20) mice. Each point represents the average of representative mice of the corresponding genotype. (B) The relative weights of male mice based on the average of age-matched ratios
over 20 weeks. (C) Kaplan-Meier survival curve of Hexa−/− and Hexa−/−Neu3−/−mice. (D) Gross appearance of four-month-old Hexa−/− (left) and Hexa−/−Neu3−/− (right) mice. (E)
X-rays of 4.5-month-old Hexa−/− and Hexa−/−Neu3−/− mice. Note the hunched posture of the Hexa−/−Neu3−/− mice. (F) Photographs of the brains from four-month-old Hexa−/−
(left) and Hexa−/−Neu3−/− (right) mice. Note that the brain of the Hexa−/−Neu3−/− mouse is 15–20% bigger in size than that of its Hexa−/− littermate.
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predominant sialidase in GM2 catabolism in Hexa−/−mice (Seyrantepe
et al., 2010).
In this study, we generated a mutant mouse line in which both Hexa
and Neu3 genes have been genetically deleted in order to explore the
metabolic bypass mechanism in the ganglioside degradation pathway.
These mice displayed massive storage of GM2 and exhibited clinical,
pathological, and biochemical abnormalities similar to Tay-Sachs pa-
tients. Our analysis of these mice indicates that Hexa−/−Neu3−/−mice
could serve as a useful model for Tay-Sachs disease and contribute to
our understanding of cellular pathologies that drive the progression of
the disease by revealing prominent neuroinflammation caused by ab-
normal lysosomal accumulation of GM2 ganglioside in neurons.
2. Materials and methods
2.1. Generation of double knockout mice
Tay-Sachs disease mice (Hexa−/−) on a 129/Sv background and
NEU3-deficient (Neu3−/−) mice on a C57BL/6 background were gen-
erated as previously described (Phaneuf et al., 1996; Yamaguchi et al.,
2012). A female Neu3−/− mouse was crossed with a male Hexa−/−
mouse to generate doubly heterozygous (Hexa+/−Neu3+/−) mice. As
doubly null (Hexa−/−Neu3−/−) mice were sterile, mice with either a
null Hexa−/− allele (Hexa−/−Neu3+/−) or a null Neu3−/− allele
(Hexa+/−Neu3−/−) were mated with each other to establish a colony.
The mice were bred in a laboratory animal facility at the Izmir Institute
of Technology. The mice were housed in groups of five per cage and
maintained at a constant temperature with an alternating 12-h light/
dark cycle. Food and water were available ad libitum. All animal ex-
periments were performed in accordance with the Turkish Institute of
Animal Health guide for the care and use of laboratory animals. The
animal studies were approved by the Institutional Animal Care and Use
Committee of the Izmir Institute of Technology. The Hexa and Neu3
genotypes were identified by PCR using genomic DNA extracted from
the tails of the mice. The wild-type (WT) and mutant Hexa alleles were
determined by PCR using AmpONE Taq DNA polymerase (GeneAll
Biotechnology Co. Ltd., Korea) and the primers HexaF (5″-GGCCAGA-
TACAATCATACAG-3″), HexaR (5″-CTGTCCACATACTCTCCCCACAT-
3″) and PGKR (5″-CACCAAAGAAGGGAGCC GGT-3″). The wild-type
primers (HexaF and HexaR) yielded a 425-bp fragment and the mutant
primers (HexaF and PGKR) yielded a 216-bp fragment. The wild-type
and mutant Neu3 alleles were determined by PCR with Taq DNA
polymerase (Invitrogen Life Technologies, USA) and the primers Neu3F
(5″-GCTCTACCCCATTCTACATCTCCAGAC-3″), Neu3R (5″-TCGTGCT-
TTACGGTATCGCCGCTCCCGATT-3″), and NeoR (5″-GTGAGTTCAA
GAGCCA TGTTGCTGATGGTG-3″). The primers Neu3F and Neu3R
generated a DNA fragment of 2110 bp derived from the wildtype allele,
whereas the primers Neu3F and NeoR generated a DNA fragment of
1689 bp derived from the targeted allele. The combination of the PCR-
based procedures for the Hexa and Neu3 alleles allowed unequivocal
identification of all four of the possible genotypes.
2.2. Quantitative gene expression assay by real-time PCR and Western
bloting
The relative expression levels of mRNA for the genes encoding
Neu1, Neu3, GM2 activator protein (GM2AP) and β-hexosaminidase B
(HEXB) were determined using LightCycler 480 SYBR Green I Master
Mix (Roche, Germany) with the glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) gene as an internal control. The total RNA was
extracted from brain tissue sections from each genotype (n= 3) using
TRIzol Reagent (Geneaid, Germany) and 50 ng/μL cDNA was synthe-
sized with a High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, USA). The real-time PCR method was optimized with 75 ng
cDNA in a 20 μL reaction mixture containing 0.4 μM primer pair and
1× Roche LightCycler 480 SYBR Green I Master Mix. The optimal PCR
conditions were determined to be as follows: 1 cycle of 10 min at 95 °C,
followed by 45 cycles of 20 s at 95 °C, 15 s at 61 °C, and 22 s at 72 °C.
Readings were taken after each cycle. After a final cycle of 30 s at 95 °C
and, 10 s at 60 °C, continuous reading was applied while increasing the
temperature to 99 °C to detect the presence of primer dimers. The
comparative threshold (CT) method was used for data analysis. Data are
reported as the mean ± SE. The p values between data sets were de-
termined by one-way-ANOVA analysis using GraphPad. Significance
was defined as p < 0.05. The following primer pairs were used for
each gene of interest: Gm2ap, APF (5″-GCTGGCTTCTGGGTCAAGAT-3″,
APR (5″-GCACTGTGAAGTTGCTCGTG-3″); Hexb, HexBF (5″-
AGTGCGAGTCCTTCCCTAGT-3″), HexBR (5″-ATCCGGACATCGTTTG
GTGT-3″); GAPDH, GapdhF (5″-CCCCTTCATTGACCTCAACTAC-3″)
and, GapdhR (5″-ATGCATTGCTGACAATCTTGAG-3″); Neu1, Neu1F
(5″-TCATCGCCATGAGGAGGTCCA-3″) and, Neu1R (5″-AAAGGGAATG
CCGCTCACTCCA-3″); Neu3, Neu3F (5″-CTCAGTCAGAGATGAGG
ATGCT-3″) and, Neu3R (5′-GTGAGACATAGTAGGCATAGGC-3′). The
total RNA was extracted from the cerebellum and cortex tissues of each
genotyped mouse using the RNeasy Mini Kit (Qiagen, Germany) fol-
lowing the manufacturer's instructions. The cDNA was synthesized
using an RT2 First Strand Kit (Qiagen, Germany) following the manu-
facturer's instructions. The relative mRNA expression of 84 key genes
involved in programmed cell death was determined using an RT2
Profiler PCR Array (Qiagen, Germany). Quantitative real-time PCR was
Fig. 3. Accumulation of ganglioside GM2 in the brains of Hexa−/
−Neu3−/− mice. The neutral (left) and acidic (right) fractions of
sphingolipids from brain tissue samples were separated by HPTLC and
stained for glycolipids. The neutral and acidic glycosphingolipid
standards are indicated on each side. (A) GA2 appears slightly above
the yellowish nonspecific staining of sphingomyelin. (B) The GM3
double band appears in the brains of Hexa−/−Neu3−/− mice. (C)
GM2 accumulation in the brains of Hexa−/− (mild) and Hexa−/
−Neu3−/− (strong) mice. Standards are as follows, from top to
bottom. S1: GalCer* (double band), LacCer, GA2, and GA1*: Contains
ceramide anchors with alpha-hydroxy fatty acids. S2: GM3, GM2,
GM1a. S3: from porcine brain, sulfatide SM4s, and the gangliosides
GM1a, GD3, GD1a, GD1b, and GT1b. These data are representative of
three samples.
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performed on a Roche LightCycler 96 instrument using RT2 Real-Time
SYBR Green PCR Mastermix (Qiagen, Germany). The expression level of
each gene was normalized using the mean expression levels of five
housekeeping genes. The data from Hexa−/−Neu3−/− mice were
compared using the data from Hexa−/−mice (control) as the calibrator.
The fold changes in the expression levels of genes were calculated ac-
cording to the 2−ΔΔCT method. Genes that exhibited positive or nega-
tive fold changes of> 1.5 were considered as increased or decreased.
For Western Blot analysis, total protein concentration from the lysates
was determined using the Bradford protein assay. Equal amount of
protein was loaded and separated in 10% SDS-PAGE, followed by
transfer to nitrocellulose membrane (Bio-Rad, USA). The membranes
were then incubated with anti-HexB (1:500, Santa Cruz, USA) and anti-
actin (1:1000, Cell Signalling, USA) antibodies at room temperature for
2 h, followed by incubation with HRP-conjugated secondary antibodies
(Jackson ImmunoResearch Lab, USA). The proteins were visualized by
LuminataTM Forte Western HRP Substrate (Millipore, USA) on a digital
imaging system (Fusion SL, Vilber). The density of bands was normal-
ized to actin and quantified using NIH ImageJ.
2.3. Glycosphingolipid (GSL) extraction and high-performance thin layer
chromatography (HPTLC)
GSLs were extracted from tissues (brain, testes, kidneys, liver, lungs,
and muscle), separated and chemically stained as described previously
(Sandhoff et al., 2002; Marsching et al., 2014) with minor modifica-
tions. In brief, the tissues were homogenized over ice, in 3 mL of me-
thanol and 300 μL of distilled water. Subsequently, 1 mL of methanol
and 3 mL of chloroform were added to the homogenates, and then the
supernatants were separated from the pellets. The pellets were re-
Fig. 4. Quantitative analysis of major brain gangliosides by LC-MS/MS. (A) GM2, (B) GM3, (C) LacCer, (D) GA2, (E) GA1, (F) GM1. Each column represents the mean ± SEM of three
samples. Statistical analysis was performed using one-way ANOVA (*p < 0.05, ***p < 0.001, and ****p < 0.0001).
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extracted with solvent mixtures of CHCl3/CH3OH/H2O, once in ratio of
10:10:1 and once in a ratio of 30:60:8, and all three supernatants were
pooled and dried to yield the raw extracts. The raw extracts were de-
salted on RP-18 columns and separated into neutral and acidic lipids on
DEAE A-25 columns. Both fractions were treated with mild base (0.1 M
KOH in CH3OH for 2 h at 37 °C) to hydrolyze ester-based phospholipids.
Finally, both fractions were desalted again using RP-18 columns. The
dried lipid fractions were taken up in the solvent mixture of CHCl3/
CH3OH/H2O in a ratio of 10:10:1. The HPTLC lanes were loaded with
lipid extracts corresponding to 2 mg tissue wet weight. After pre-de-
velopment of the loaded HPTLC plates with chloroform/acetone in a
ratio of 1:1, plates were dried and developed with CHCl3/CH3OH/0.2%
aqueous CaCl2, then dried and stained with orcinol to reveal sugar-
containing compounds.
2.4. GSL extraction and LC-ESI-MS/MS analysis
GSLs were extracted from tissues as described for the HPTLC ana-
lysis, except for the separation step using DEAE A-25 columns. Aliquots
corresponding to 1 mg tissue wet weight were mixed with 12 pmol of
each of the following internal standards: LacCer(d18:1/14:0), LacCer
(d18:1/19:0), LacCer(d18:1/27:0), GA2(d18:1/19:0), GA1(d18:1/
19:0), GM3(d18:1/19:0), GM2(d18:1/14:0), and GM1a(d18:1/19:0).
The standards were synthesized from commercially available lyso-GSLs
Fig. 5. (A–D) Relative levels of Hexb and Gm2ap mRNA in the cerebella and cortices of 2.5- and 4.5-month-old WT, Hexa−/−, Neu3−/−, and Hexa−/−Neu3−/−mice (GAPDH mRNA was
used to normalize the level of the gene of interest for all samples, n= 3). Statistical analysis was performed using one-way ANOVA (*p < 0.05, **p < 0.005, ***p < 0.001, and
****p < 0.0001). (E, F) Western blot analysis using anti-HEXB antibody also revealed a significantly higher level of HEXB in the cortices of (E) Hexa−/−Neu3−/− mice compared to (F)
Hexa−/− mice.
V. Seyrantepe et al. Experimental Neurology 299 (2018) 26–41
31
and the corresponding activated fatty acids as described previously
(Sandhoff et al., 2002), or from commercially available GSLs, that were
first converted into the corresponding lyso-GSLs by SCDase treatment
according to a literature method (Sandhoff et al., 2002). The samples
spiked with the internal standards were dissolved in 60% aqueous
methanol. LC-MS/MS analysis was performed on a Xevo TQ-S tandem
mass spectrometer with an ESI-source coupled to an automated Acquity
I Class UPLC system using an Acquity UPLC BEH C18 1.7 μm column
(50 mm length, 2.1 mm diameter), all from Waters Corp. The column
was equilibrated with solvent system A (methanol/water/formic acid
(60:40:0.2 v/v/v), containing 10 mM ammonium formate), and lipids
were eluted with an increasing proportion of solvent system B (2-pro-
panol/methanol/water/formic acid (20:79:1:0.2 v/v/v/v) containing
10 mM ammonium formate) at a flow rate of 0.45 mL/min (see Table 1
for the gradient used).
Aliquots of 10 μL were injected for each run. The GSLs were de-
tected in positive ESI mode using the selected reaction monitoring
mode with the transition of the [M + H]+ molecular ions to the pro-
duct sphingoid base ion at m/z 264 (i.e. (So[d18:1) + H− 2H2O]+).
The following collision energies were used: LacCer, 57 eV; GA2, 57 eV;
GA1, 65 eV; GM3, 48 eV; GM2, 57 eV, and GM1, 65 eV. GSLs con-
taining a C18-sphingosine and a C16:0-, C18:0-, C20:0-, C22:0-,
C24:1-,or C24:0-acyl chain were monitored. For quantification, the
peak areas of the individual lipid species were divided by the respective
average internal standard area, multiplied by the amount of this in-
ternal standard, and finally divided by the tissue wet weight used.
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Fig. 6. Neuropathology of Hexa−/−Neu3−/− mice compared with WT and Hexa−/− mice. Sections from the cortices of (A, B) 4.5-month-old WT and (C, D) Hexa−/− mice showing the
absence of vacuolization. (E, F) Vacuolated neurons in the cerebellar nucleus of Hexa−/−Neu3−/−mice. (G–M) Sections from the cerebella of (G, H) 4.5-month-old WT and (I, K) Hexa−/
− mice, showing the normal Purkinje cell layer that is absent in (L, M) Hexa−/−Neu3−/− mice.
Fig. 7. Transmission electron micrographs of neuronal inclusions in the cortex and in-
creased number of lysosomes. (A) WT, (B) Hexa−/−, (C) Neu3−/−, and (D) Hexa−/
−Neu3−/− mice. N: nucleus; L: lysosomes; nu: nucleolus.
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2.5. MALDI-TOF MS imaging
The frozen brains of transgenic and control mice (4.5 month old)
were mounted onto a metal chuck with frozen section compound and
cut into 10 μm cryosections using a Leica cryostat, according to a lit-
erature procedure (Fulop et al., 2013). The cryosections were thaw-
mounted onto precooled conductive indium tin oxide (ITO) slides. Be-
fore application of the matrix, the ITO slides were desiccated overnight
under vacuum at room temperature. A 5 mg/mL solution of phenyl-
cyano-cinnamamide (Sirius Fine Chemicals (SiChem) GmbH, Bremen)
in acetonitrile/water (90:10 v/v) was applied to the tissue sections by
spray coating using the following parameters of the SunCollect device
(SunChrom, Friedrichsdorf, Germany). First, three initial matrix layers
were applied using flow rates of 10 μL/min, 15 μL/min, and 20 μL/min
followed by six layers at 25 μL/min with a velocity of 1000 mm/min to
ensure a homogeneous matrix layer on the tissue slides. MALDI imaging
mass spectrometry (MALDI-IMS) was performed in negative linear
mode in the m/z range of 900–2600 using an Autoflex Speed TOF/TOF
with a 2000 Hz modulated Nd:YAG laser (355 nm) and the FlexImaging
4.0 software (Bruker Daltonics). Prior to analysis, the acquisition
method was calibrated using the total ganglioside porcine brain extract
(Avanti Polar Lipids, Inc., Alabaster, AL, USA). A total of 200 laser shots
were accumulated per raster spot with a laser width of 100 μm. In
addition, baseline subtraction was performed and the images were vi-
sualized after total ion current (TIC)-normalization.
2.6. Histopathology and immunohistochemistry
Mice of the indicated ages (n= 3) were anesthetized and perfused
through the heart with 4% paraformaldehyde (Sigma) in phosphate-
buffered saline (PBS; pH 7.4). The brains were removed and placed in
the same fixative overnight at 4 °C and then treated sequentially with
10%, 20%, and 30% sucrose in PBS overnight at 4 °C. Coronal brain
sections were embedded in optimal cutting temperature (OCT) com-
pound (Sigma), sectioned at 10 μm thickness, and mounted on
HistoBond® microscope slides (Marienfeld) at −20 °C using a Leica
cryostat. The 10 μm coronal brain sections from the mice at the in-
dicated ages were stained with Gill's hematoxylin (Merck, Germany) for
3 min, followed by differentiation in 70% ethanol:1 N HCl (99:1, v/v),
washing under running tap water, and staining with eosin Y solution
0.5% alcoholic (Merck, Germany) for 1 min. The sections were dehy-
drated with alcohol and xylene. Terminal dUTP nick end-labeling
(TUNEL) analysis was performed using the ApopTag Fluorescein in Situ
Apoptosis Detection Kit (Millipore) according to the manufacturer's
specifications. Briefly, brain sections from each group (n= 4) were
fixed with paraformaldehyde and ethanol:acetic acid solution (2:1).
Sections were incubated with terminal deoxynucleotidyl transferase
followed by incubation with an anti-digoxygenin conjugate. Propidium
iodide (0.5 μg/mL) was added as a nuclear counterstain. Images were
obtained using fluorescent microscope (Olympus) with ×10 magnifi-
cation. Cerebellum and hippocampus were scanned for positive green
fluorescent cells as an indicator of apoptosis. For the im-
munohistochemical studies, the slides were treated with ice-cold
acetone and then, blocked in a humidified chamber with blocking
buffer (4% BSA, 10% goat serum, and 0.3 M glycine in PBS) 1 h at room
temperature. Anti-GM2 (GM2 ganglioside; KM966) and anti-LAMP1
(lysosomal-associated membrane protein 1; Abcam, USA) were diluted
to 1:500 in the blocking buffer and applied overnight at 4 °C. The
binding of the anti-GM2 and anti-LAMP1 antibodies was visualized
using goat anti-human DyLight 488 (Thermo, USA) and goat anti-rabbit
Alexa Fluor 568 (Abcam, USA) fluorescent antibodies, respectively. The
slides were also blocked in a humidified chamber with 5% goat serum
and 0.3% Triton X-100 in PBS. Anti-GFAP (glial fibrillary acidic protein;
Sigma, Germany) was diluted to 1:200 in blocking buffer and applied
Fig. 8. Transmission electron micrographs showing the accumulation
of inclusions in cerebellar and cerebral cortex neurons, testis, and
kidney tissues from 4.5-month-old Hexa−/−Neu3−/− mice. (A, B)
Representative cerebellar tissue micrographs. (A) Purkinje cells ex-
hibit numerous cytoplasmic inclusions (arrows). (B) At a high mag-
nification, a granular cell shows cytoplasmic inclusions (arrow) with
lamellar membrane structure. N, nucleus of the Purkinje cell. Scale
bars: A, 5 μm; B, 500 nm. (C, D) Representative cerebral tissue mi-
crographs. (C) Neurons exhibit numerous cytoplasmic inclusions
(arrow). (D) A possible degenerating neuron shows cytoplasmic in-
clusions (arrow). N, nucleus of the neuron. Scale bars: C and D, 2 μm.
(E) Representative testis tissue micrograph. Cytoplasmic inclusions
(arrow) were observed in the Sertoli cell. S, Sertoli cell nucleus. Scale
bar, 5 μm. (F) Representative renal tissue micrograph. A renal tubule
cell (distal tubule) near the lumen (L) shows numerous cytoplasmic
inclusions (arrow). Scale bar, 2 μm. These data are representative of
two samples.
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overnight at 4 °C. The binding of GFAP was visualized using goat anti-
mouse Alexa Fluor 488 antibody. The slides were mounted with
Fluoroshield mounting medium with DAPI (Abcam, USA) and images
were obtained using fluorescence microscopy (Olympus, Germany).
2.7. Transmission electron microscopy
Brain (temporal area of the cerebral cortex and cerebellar cortex),
testis and kidney tissues were dissected from 4.5-month-old Hexa−/
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Fig. 9. Immunohistochemistry with anti-GM2 and anti-LAMP2 antibodies to detect the lysosomal storage of GM2 ganglioside in the hippocampi and cerebella of 4.5-month-old WT (I, V),
Hexa−/− (J, W), Neu3−/− (K, X) and Hexa−/−Neu3−/− mice (L, Y).
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−Neu3−/− mice. The tissue pieces were immersed in 2.5% glutar-
aldehyde in 0.1 M phosphate buffer (pH 7.4), post-fixed in 1% osmium
tetroxide in dH2O, dehydrated using a graded acetone series, and em-
bedded in Araldite CY-212. Semi-thin sections (1 μm thick) were pre-
pared and stained with toluidine blue and then examined under a light
microscope to select areas for histological evaluation of the tissues.
Ultrathin sections (40–60 nm thick) were prepared, placed on copper
grids (200 mesh), and double stained with uranyl acetate and lead ci-
trate prior to examination using Zeiss Libra 120 electron microscope
(Carl Zeiss Microscopy GmbH, Germany).
2.8. Footprint analysis
WT (n= 3), Hexa−/− (n= 3), Neu3−/− (n= 3), and Hexa−/
−Neu3−/− (n= 3) mice at the age of 4.5 months were subjected to the
footprint test. The fore and hind paws of theWT, Hexa−/−, Neu3−/−, and
Hexa−/−Neu3−/− mice were painted with nontoxic ink. The animals
were then allowed to walk along a runway (50 cm long, and 10 cm wide
(with 10 cm high walls) into an enclosed box on white paper. Their
walking patterns were recorded using a scanner (HP). To avoid possible
confounding effects in gait abilities, a separate set of animals were used.
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Fig. 10. (A) Cell death was determined using the TUNEL assay for the cerebella and hippocampi from 4.5-month-old WT, Hexa−/−, and Hexa−/−Neu3−/− mice. Numerous TUNEL-
positive neurons were observed (yellow). Nuclei are counterstained in red. (B, C) Relative expression levels of pro-apoptotic and anti-apoptotic genes in the cortices and cerebella of
Hexa−/−Neu3−/−mice (n= 3) at the age of 4.5 months, normalized to Hexa−/−mice (n= 3). (For interpretation of the references to color in this figure legend, the reader is referred to
the web version of this article.)
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2.9. Rotarod test
WT (n= 8), Hexa−/− (n= 7), Neu3−/− (n= 10), and Hexa−/
−Neu3−/− (n= 11) mice at the age of 2.5 months; WT (n= 7),
Hexa−/− (n= 6), Neu3−/− (n= 5), and Hexa−/−Neu3−/− (n= 2)
mice at the age of 3.5 months; and WT (n= 19), Hexa−/− (n= 14),
Neu3−/− (n= 17), and Hexa−/−Neu3−/− (n= 16) mice at the age
4.5 months were subjected to a rotarod test to evaluate motor co-
ordination and balance. The mice were first trained to walk on the
rotarod at a constant rotation speed of 5 rpm for a maximum of 5 min.
The testing session was performed with the rotarod rotating at an in-
creasing speed (4 to 40 rpm over 5 min). The latency to fall was re-
corded using Sedacom version 2.0 (Harvard Apparatus). The mice were
required to perform three trials for each test and time point, with a rest
period of 15 min between trials. In the analysis, the mean latency to fall
of three trials was used.
3. Results
3.1. Generation of a Hexa−/−Neu3−/− mouse strain
The Hexa−/− and Neu3−/− mice were generated previously
(Phaneuf et al., 1996; Yamaguchi et al., 2012) and interbred to produce
the Hexa−/−Neu3−/− double-knockout mice. The mice were bred as
heterozygous to produce WT, Hexa−/−Neu3+/+, and Hexa+/+Neu3−/
−mice along with the Hexa−/−Neu3−/−mice. The Hexa gene, encodes
the α subunit of β-hexosaminidase A (HEXA) and the Neu3 gene, en-
codes plasma-membrane-associated sialidase (NEU3). Based on pre-
vious data suggesting the existence of a glycosphingolipid degradation
bypass pathway as shown in Fig. 1A, we predicted that the deletion of
both of these enzymes would completely block the degradation of GM2
ganglioside in mice (Yamanaka et al., 1994; Sango et al., 1995; Phaneuf
et al., 1996). To elucidate the identity of the sialidase(s) responsible for
phenotypic rescue in Hexa−/− mice, we first assessed the expression
levels of all of the sialidase genes (Neu1-Neu4) that might participate in
a metabolic bypass pathway. We used quantitative RT-PCR to analyze
the changes in the expression levels of the sialidase genes from different
sections of the brains of WT and Hexa−/− mice. In this analysis, Neu2
and Neu4 showed no differences in their relative expression levels be-
tween WT and Hexa−/− mice (data not shown), while the expression
levels of Neu1 and Neu3 were increased significantly in the cerebellum,
cortex, hippocampus, and thalamus of Hexa−/− mice compared to WT
mice. The results indicated that the Neu1 gene is by far the most in-
duced sialidase gene in the mouse brain (Fig. 1B). NEU1 is also the
sialidase most likely to account for the metabolic bypass seen in Hexa−/
−mice, because it is involved in the NEU1/cathepsin A/β-galactosidase
complex found in the lysosomes. Additionally, an earlier study de-
monstrated that the lysosomal storage of GM2 ganglioside in human
Tay-Sachs neuroglia cells and skin fibroblasts could be overcome by
overexpressing human NEU1/cathepsin A, suggesting that at least the
first response of the metabolic bypass is related to an increase in sia-
lidase expression (Igdoura et al., 1999). Interestingly, the mRNA ex-
pression of Neu3, also increased in response to a block in GM2 gang-
lioside degradation (Fig. 1C). Furthermore, the expression of Neu3 was
low in normal mice but was induced by 1.5–2.0 fold in whole brain
sections of Hexa−/−mice. Based on the observed expression patterns of
the sialidases, we postulated that the induction of Neu3, either in-
dependently or in concert with Neu1, underscored the metabolic by-
pass, preventing the accumulation of GM2 that was expected to occur in
Hexa−/− mice.
3.2. A severe and progressive phenotype in Hexa−/−Neu3−/− mice
Viable Hexa−/−Neu3−/− mice were obtained at the frequency ex-
pected by Mendelian considerations, indicating the absence of em-
bryonic lethality. At birth, no differences could be observed between
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Fig. 11. Immunohistochemical analysis of astrocytes. Sections from the hippocampi, cortices, and cerebella of 4.5-month-old (A–C) WT, (D–F) Hexa−/−, (G–I) Neu3−/− and (J-L) Hexa−/
−Neu3−/− mice were immunostained with GFAP to detect reactive astrogliosis. These data are representative of three samples.
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WT, Hexa−/−, Neu3−/−, and Hexa−/−Neu3−/− mice. However,
growth delay became apparent in Hexa−/−Neu3−/− mice after the age
2.5-months. Hexa−/−Neu3−/− mice developed body weight similar to
WT, Hexa−/−, and Neu3−/− mice until 14 to 15 weeks of age, but then
body weight declined in contrast to the other three mouse lines. At
20 weeks of age Hexa−/−Neu3−/− reached the same weight again,
which they had at 8 weeks (Fig. 2A, B, C). Furthermore, the Hexa−/
−Neu3−/− mice were approximately 15–20% smaller than the Hexa−/
− mice (Fig. 2D), while the radiographic analysis revealed a hunched
posture in the Hexa−/−Neu3−/− mice similar to previously described
the mice lacking both subunits of lysosomal beta-hexosaminidase
(Fig. 2E) (Sango et al., 1995). The locomotor activities of the Hexa−/
−Neu3−/− mice gradually decreased after birth, and, ataxia and tre-
mors later developed. By four months after birth, they had started to
exhibit gait disturbance with severe shaking. The majority of the
Hexa−/−Neu3−/− mice died by the age of 3–4 months and only a few
lived to five months. At the age of 4.5 months, the brains of the Hexa−/
−Neu3−/− mice were morphologically intact but significantly heavier
than those of their single-knockout and WT littermates (data not
shown), suggesting severe lipid accumulation in the brain. In contrast,
the brains of the Hexa−/−Neu3−/− mice showed only a slight increase
in size (Fig. 2F). The single-knockout mice survived longer than
1.5 years and exhibited no neurological abnormalities in comparison to
the double-knockout mice. Furthermore, the heterozygous mice
(Hexa+/−Neu3−/− or Hexa−/−Neu3+/−) exhibited no obvious ab-
normalities. Both male and female Hexa−/−Neu3−/− mice were sterile
and never produced offspring when crossed with WT mice on either
C57BL/6 or 129/sv backgrounds.
3.3. Abnormal accumulation of GM2 ganglioside observed in the brain and
visceral organs
As shown in Fig. 3, HPTLC analysis of the acidic and neutral gly-
colipids was performed for samples of the brains (4.5 months of age)
and visceral organs (kidneys, lungs, liver, muscle, and testes;
2.5 months of age) of Hexa−/−Neu3−/− mice (Supplementary Mate-
rials S3–S7), which revealed a severe block in GM2 degradation. The
abnormal accumulation of otherwise minor acidic gangliosides (GM2
and GM3) was observed in the brain and other tissues of Hexa−/
−Neu3−/− mice. The accumulation of GM2 was especially severe.
Slightly higher neutral glycosphingolipid (GA2) levels were detected
only in the Hexa−/−Neu3−/− mice. Mass spectrometric analysis re-
vealed the accumulation of GM2 (Fig. 4A) and GM3 (Fig.4B) as well as
lactosylceramide (Fig. 4C) and GA2 (Fig. 4D), but not GA1 (Fig. 4E) or
GM1 (Fig. 4F) in the brain glycosphingolipid extracts of the Hexa−/
−Neu3−/− mice. However, the slightly higher level of LacCer and the
lower level of GA1 in Neu3−/− mice was not significant compared to
Hexa−/− and WT mice, respectively (Fig. 4C, E).
The analysis of sagittal mouse brain sections by MALDI-IMS con-
firmed the massive accumulation of GM2, in the whole brain, and
especially in the cerebellum, hippocampus, and cortex, whereas the
minor accumulation of GA2 was mainly concentrated in the cerebellum
(Supplementary Material S1).
3.4. Hexa−/−Neu3−/− mice exhibit increased expression levels of HEXA
associated proteins
Significantly higher levels of Hexb mRNA were observed in the
cerebellum of Hexa−/−Neu3−/− mice (4.5 months old) compared to
Hexa−/− (Fig. 5A). In addition, significantly higher levels of Hexb
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Fig. 12. (A) Footprint analysis to evaluate the walking patterns in terms of stride length (1), sway length (2), and stance length (3) of 4.5-month-old WT, Hexa−/−, Neu3−/−, and Hexa−/
−Neu3−/−mice. The histograms represent the mean values of each parameter ± SEM. (B) Stride length, (C) sway length, and (D) stance length. Statistical analysis was performed using
one-way ANOVA (*p < 0.05, **p < 0.025, ***p < 0.001, and ****p < 0.0001).
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mRNA (Fig. 5B), and its coding protein (Fig. 5E, F) were observed in the
cortex of Hexa−/−Neu3−/− and Neu3−/− mice compared to Hexa−/−
and WT mice, respectively. However, the expression level of Gm2ap
mRNA was significantly higher only in the cerebellum of Hexa−/
−Neu3−/− and Neu3−/− mice (4.5 months old) compared to Hexa−/−
and WT mice, respectively (Fig. 5C, D).
3.5. Hexa−/−Neu3−/− mice recapitulated key pathological features of
human Tay-Sachs disease
Histological evaluation of the brains of the Hexa−/−Neu3−/− mice
revealed striking vacuolization. For example, the Purkinje cells were
specifically affected in the cerebellum (Fig. 6L, M). Light microscopy
also revealed cytoplasmic inclusions in the Purkinje cells (Supplemen-
tary Material S2A), and neurons (Supplementary Material S2B). The
vacuolated monocytes (Supplementary Material S2E) were also ob-
served in the peripheral blood. Electron microscopic analysis demon-
strated an abnormal increase in lysosomes in Hexa−/−Neu3−/− mice,
which is a prominent morphological marker of distressed neurons that
is associated with neurodegenerative diseases (Fig. 7A, D). We also
observed membranous cytoplasmic bodies that appeared as concentric
ring-like structures in the neuronal lysosomes, like those reported in
human Tay-Sachs patients (Fig. 8A, D). The inclusions of many small
vesicles and complex lamellar structures observed in the kidney and
testis samples could be the cause of urinary retention and infertility in
Hexa−/−Neu3−/− mice (Fig. 8E, F). Immunohistochemical staining
with anti-GM2 and anti-LAMP1 antibodies demonstrated the accumu-
lation of GM2 in the brains of Hexa−/−Neu3−/− mice, especially in
cerebellum and hippocampus (Fig. 9). Terminal deoxynucleotidyl
transferase (TdT) dUTP nick-end labeling (TUNEL) assays showed ele-
vated levels of cell death in the cerebella and hippocampi of Hexa−/
−Neu3−/−mice compared to the WT and Hexa−/−mice (Fig. 10A). To
verify the increased levels of apoptosis in the cortex and cerebellum, the
RNA levels of 84 different pro-apoptotic (Fig. 10B) and anti-apoptotic
(Fig. 10C), genes were analyzed. Among the pro-apoptotic genes, that
for tumor necrosis factor α (TNF-α) exhibited the highest expression
ratio (approximately six fold in the cerebellum) in the Hexa−/−Neu3−/
− mice. TNF-α, which is involved in both pro-inflammatory and
apoptotic signaling cascades, is a key mediator of inflammation as well
as apoptosis. Several studies have shown that the absence of TNF-α,
leads to significantly less inflammation, apoptosis, and fibrosis
(Rimkunas et al., 2009). Caspase-4 (CASP4) also exhibited a twofold
increase in the cerebellum of Hexa−/−Neu3−/− mice. Although CASP4
is a poorly characterized member of the caspase family, its involvement
in endoplasmic reticulum stress-induced apoptosis has been suggested.
The elevated levels of CASP4 suggest increased apoptosis in the cere-
bella and cortices of Hexa−/−Neu3−/− mice (Sollberger et al., 2012).
The early activation of astrocytes in mouse models of GM2 gang-
liosidoses has been reported (Kawashima et al., 2009). Of the anti-
apoptotic genes analyzed, the expression of Naip (neuronal apoptosis
inhibitory protein-1) in Hexa−/−Neu3−/− mice was dramatically de-
creased (approximately sevenfold in the cerebellum and three fold in
the cortex) compared to Hexa−/− mice, indicating that NAIP1 cannot
inhibit apoptosis (Lesné et al., 2005). The peroxiredoxin II (Prdx2) gene
encodes a protein that reduces peroxide levels in cells. We speculate
that the lower expression of this protein (approximately twofold in the
cerebellum and fourfold in the cortex) in Hexa−/−Neu3−/−mice might
be important, because PRDX2 plays a major role in protecting red blood
Fig. 13. The rotarod test uses the time on the rod to test motor coordination and balance of (A) 2.5-, (B) 3.5-, and (C) 4.5-month-old WT, Hexa−/−, Neu3−/−, and Hexa−/−Neu3−/−
mice. (D) Age dependent motor function and motor learning of Hexa−/−Neu3−/− mice was compared with its age matched counterparts. The speed was accelerated from 4 rpm to
40 rpm over a five-minute period. Data show the mean ± SEM. Statistical analysis was performed using one-way ANOVA (*p < 0.05, **p < 0.025, ***p < 0.001, and
****p < 0.0001).
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cells from oxidative stress in mice (Lee et al., 2003). X-linked inhibitor
of apoptosis (Xiap) is another gene that exhibited decrease (twofold) in
the cortex (Bhattacharyya and Banerjee, 1997). DNA polymerase β
(polβ) carries out base-excision repair (BER), which is required for DNA
maintenance, replication, recombination, and drug resistance. De-
creased expression of the polβ gene (twofold in the cerebellum and 4.4
fold in the cortex) may result in mutations and, increased chromosomal
damage as well as apoptosis (Sobol et al., 2000). We also observed
decreased expression of genes encoding general inhibitors of apoptosis,
including Bax, Bcl2, Bcl2l1, Bcl2l10, and Bcl2i12, which prevents them
from inhibiting apoptosis. Glial fibrillary acidic protein (GFAP) im-
munohistochemistry revealed strong astrogliosis in various brain re-
gions of Hexa−/−Neu3−/− mice, with the most prominent GFAP
staining observed in the hippocampus, cerebral cortex, and thalamus
(Fig. 11). In accordance with this result, significant increases in the
expression levels of the Ccl3 (MIP1α) and Ccl4 (MIP1β) chemokines in
the cerebellum and Ccl2 as well as Ccl3 in cortex of Hexa−/−Neu3−/−
mice compared to age-matched Hexa−/− mice were detected at four
months of age (data not shown). Most of the progressive neuropatho-
logical changes such as the elevated astrogliosis positive cells observed
in Hexa−/−Neu3−/−mice, closely resemble those of the Hexb−/−mice
model of Sandhoff disease.
3.6. Hexa−/−Neu3−/− mice exhibit gait abnormalities and motor
coordination deficits
Throughout their observed lifespans, the WT, Hexa−/−, and Neu3−/
− mice were grossly indistinguishable and were grouped together as
controls for all analyses. To quantify gait abnormalities in the Hexa−/
−Neu3−/− mice, we analyzed their footprint patterns as they walked
across a platform (Fig. 12). The Hexa−/−Neu3−/− mice tended to stay
at the start line and took longer than the WT, Hexa−/− or Neu3−/−
mice to walk the length of the platform. The stride, sway, and stance
lengths for the Hexa−/−Neu3−/− mice were significantly reduced and
more variable than their littermate controls. The paw prints of the mice
reflect the affected neurons controlling the hind legs. Motor coordina-
tion and balance were further studied using procedures similar to our
previously published methods (Seyrantepe et al., 2010). The Hexa−/
−Neu3−/− mice also exhibited progressively impaired performance on
the rotarod tests that were conducted when the mice were 2.5 and
4.5 months of age. They performed poorly during the first trial of the
stationary rod component compared to the control group, but then the
groups performed comparably for the next three trials. The Hexa−/
−Neu3−/− mice exhibited greater performance impairments on the
accelerating rotarod test (Fig. 13).
4. Discussion
To obtain animal models of GM2 gangliosidoses, Hexa−/−, Hexb−/
−, and Gm2ap−/− knockout mice have been generated (Lawson and
Martin, 2016). Naturally occurring Jacob sheep, feline, canine and
flamingo models of GM2 gangliosidoses are also known to exist. Jacob
sheep appear to mimic the human Tay-Sachs phenotype to a large ex-
tent, but a mouse model recapitulating the human disease could facil-
itate the study of disease pathogenesis. In contrast to the late-onset mild
phenotype of the Hexa−/− mouse model (Miklyaeva et al., 2004), the
Hexa−/−Neu3−/− mice displayed a lethal early-onset phenotype re-
sembling human Tay-Sachs disease. Neurological abnormalities in-
cluding tremors and ataxia as well as weakened hind limbs with un-
coordinated gait were observed. As in the case of patients with Tay-
Sachs disease, the Hexa−/−Neu3−/− mice suffer from growth impair-
ment and remain smaller than their littermates throughout their life-
span. This feature is not characteristic of the Hexa−/− mice. The
Hexa−/−Neu3−/− mice also exhibit progressive neurodegeneration
and neurobehavioral abnormalities that are similar to the severe
phenotype of Hexb−/− mice (Phaneuf et al., 1996; Yamanaka et al.,
1994; Sango et al., 1995). A high incidence of sudden death was also
common among the Hexa−/−Neu3−/− mice.
In this study we demonstrated that the combined disruption of the
genes encoding Hexa and Neu3 blocked the degradation of gangliosides
and resulted in abnormally high levels of GM2, which is consistent with
the existence of a metabolic bypass pathway in mice as was predicted
about 20 years ago. The minor accumulation of GA2 observed in par-
allel could indicate a minor contribution of NEU4 to this pathway and
the subsequent trapping of GA2 in the multi-lamellar lysosomal inclu-
sions. It is also noteworthy that lactosylceramide accumulated as much
as GM3 in the brains of 4.5-month-old Hexa−/−Neu3−/− mice, either
by trapping in inclusions or as a result of the lack of NEU3, which would
support a role of NEU3 in GM3 degradation as previously proposed
(Pan et al., 2017).
Numerous efforts are being made toward the development of
treatments for GM2 gangliosidoses. Like other lysosomal storage dis-
eases, the challenge is to reach the affected cells that store accumu-
lating macromolecules in swollen lysosomes. Approaches such as en-
zyme therapy (Tsuji et al., 2011), gene therapy (Bourgoin et al., 2003;
Martino et al., 2005; Cachon-Gonzalez et al., 2006), substrate depri-
vation therapy (Platt et al., 1997; Platt and Butters, 2000; Shapiro et al.,
2009; Bembi et al., 2006), and chaperone-mediated enzyme stabiliza-
tion (Tropak et al., 2004) have shown various levels of success in cell
cultures and some animal models, but they have yet to arrest the
neurodegenerative process in human patients. Nevertheless, the recent
promise of a novel self-complementary adeno-associated virus vector
carrying a new variant of the human HEXA α subunit and its wide-
spread distribution capacity to degrade long-standing GM2 storage in
Hexa−/− mice suggests potential for this approach in the long term
(Karumuthil-Melethil et al., 2016).
Tay-Sachs is a rare childhood disease and there is limited access to
brain samples for autopsy. Therefore, the onset and age-dependent
morphological changes in the brain and the disease mechanisms that
contribute to the neuropathology in these patients remain largely un-
known. The general similarity of the Hexa−/−Neu3−/− mouse model
to human Tay-Sachs patients renders the murine model a valuable tool
for studies of the pathogenesis and the cascade of events leading from
lysosomal dysfunction to neurodegeneration and devastating disease in
children. The feasibility of various therapeutic options including sub-
strate deprivation and gene therapy, can be investigated with this
model. Furthermore, as the rapidly progressive neurological manifes-
tations are easily recognizable both pathologically and clinically, this
mouse model is particularly useful for the evaluation of molecular
therapeutic effects on the central nervous system.
Together, our findings provide compelling evidence for undertaking
detailed studies to investigate the involvement of sialidase NEU3 in
ganglioside degradation in the pathogenesis of Tay-Sachs disease in
mice. The Hexa−/−Neu3−/− mouse model now also provides the basis
to undertake studies on human NEU3 in this mouse model in order to
estimate the therapeutic potential of possible treatments. The regula-
tion of Neu3 expression may pave the way toward novel and effective
treatment options in the management of this disease.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.expneurol.2017.09.012.
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